Next Generation Diabetes Therapy and Drug Delivery Market by Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, and Artificial Pancreas), Demographic [Adult Population (>14 years) & Child Population (< 14 years)], Indication (Type 1 Diabetes & Type 2 Diabetes), and End Users (Diagnostics/Clinics, ICUs, and Home Healthcare) - Global Opportunity Analysis and Industry Forecast, 2014-2023Next generation diabetic therapy and drug delivery systems are used to improve the adherence to insulin in diabetic patients to reduce the risk of complications related to sudden change in the blood sugar level. Oral & inhalable insulin painlessly manage the blood glucose level, and is expected to replace the injectable insulins. The use of advanced diabetic systems, such as insulin patches, CGM systems, and artificial pancreas is expected to maintain adherence to medication in diabetic patients and improve the quality of life of diabetic patients. The global next generation diabetes therapy and drug delivery market was valued at $617 million in 2015, and is estimated to reach $9,673 million by 2023, registering a CAGR of 41.1% from 2016 to 2023.
The global next generation diabetes therapy and drug delivery market is segmented based on product type, demographic, indication, end user, and geography. Based on product type, it is classified into inhalable insulin, oral insulin, insulin patches, continuous glucose monitoring (CGM) systems, and artificial pancreas. Based on demographics, it is bifurcated into adult population (>14 years) and child population (=14 years). Based on indication, it is divided into type 1 diabetes and type 2 diabetes. Based on end users, it is categorized into diagnostic/clinic, ICU, and home healthcare. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The market growth is attributed to the rise in the number of diabetic patients globally and the increase in disposable income among these patients. The benefits of using these advanced devices over conventional products, such as painless mode of insulin delivery and improvement in adherence to medication, and rise in the healthcare expenditure are expected to increase the demand for these products, thus fueling the market growth. However, lack of awareness, cost restrains in the developing regions, and less variability in products are expected to hamper the growth.
KEY MARKET BENEFITS
This report offers a detailed quantitative analysis of the current market trends from 2014 to 2023 to identify the prevailing opportunities.
The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
The global market is comprehensively analyzed with respect to product type, demographic, indication, end user, and geography.
In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY PLAYERS PROFILED
Johnson & Johnson
Senseonics Holding, Inc.
KEY MARKET SEGMENTS
By Product Type
Adult Population (>14years)
Child Population (=14years)
Type 1 Diabetes
Type 2 Diabetes
By End User
Rest of Europe
Rest of Asia-Pacific
Republic of South Africa
Rest of LAMEA
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2. EXECUTIVE SUMMARY
2.1.1. CXO perspective
CHAPTER 3. MARKET OVERVIEW
3.1. KEY BENEFITS
3.1.1. Top investment pockets
3.1.2. Top winning strategies
3.2. PATENT ANALYSIS
3.2.1. Patent analysis by year
3.2.2. Patent analysis by region
3.2.3. Patent analysis by product type
3.3. GOVERNMENT REGULATIONS AND REIMBURSEMENT POLICIES
3.4. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET
3.4.1. Smart contact lenses for glucose monitoring
3.4.2. SmartGuard GlucoSitter
3.4.3. iLet Bihormonal bionic pancreas
3.4.4. Glucose nanosensors
3.4.5. Engineering beta-cell replacement therapy
3.4.6. Glucose-responsive insulin-producing cells
3.5. MARKET DYNAMICS
184.108.40.206. Rise in incidence of diabetes along with increase in disposable income
220.127.116.11. Rise in healthcare expenditure
18.104.22.168. Benefits of using next generation diabetic products over conventional products
22.214.171.124. Cost restrains
126.96.36.199. Lack of awareness
188.8.131.52. Less variability in products
184.108.40.206. Developing products with fewer side effects at affordable costs
220.127.116.11. High undiagnosed diabetic patient population
18.104.22.168. Tapping potential in developing regions
CHAPTER 4. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT TYPE
4.1.1. Market size and forecast
4.2. INHALABLE INSULIN
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.3. ORAL INSULIN
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.4. INSULIN PATCHES
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
4.6. ARTIFICIAL PANCREAS
4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast
CHAPTER 5. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS
5.1.1. Market size and forecast
5.2. ADULT POPULATION (>14YEARS)
5.2.1. Market size and forecast
5.3. CHILD POPULATION (14YEARS)
5.3.1. Market size and forecast
CHAPTER 6. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATIONS
6.2. TYPE I DIABETES
6.2.1. Market size and forecast
6.3. TYPE II DIABETES
6.3.1. Market size and forecast
CHAPTER 7. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USERS
7.1.1. Market size and forecast
7.2.1. Market size and forecast
7.3.1. Market size and forecast
7.4. HOME HEALTHCARE
7.4.1. Market size and forecast
CHAPTER 8. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY
8.1. NORTH AMERICA
8.1.1. Key market trends
8.1.2. Key growth factors and opportunities
8.1.3. Market size and forecast
8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast
8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast
8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast
CHAPTER 9. COMPANY PROFILES
9.1 ABBOTT LABORATORIES
9.1.1 Company Overview
9.1.2 Operating Business Segment Overview
9.1.3 Financial performance
9.1.4 Strategic moves and developments
9.1.5 Key strategic moves & developments
9.2 DEXCOM, INC.
9.2.1 Company overview
9.2.2 Operating Business Segment Overview
9.2.3 Business performance
9.2.4 Key Strategies and development
9.2.5 Key strategic moves & developments
9.3 ENTERIS BIOPHARMA
9.3.2 Operating Business Segment Overview
9.3.3 Financial performance
9.3.4 Strategic moves and developments
9.3.5 Key strategic moves & developments
9.4 JOHNSON & JOHNSON
9.4.1 Company overview
9.4.2 Operating Business Segment Overview
9.4.3 Business performance
9.4.4 Strategic moves and developments
9.4.5 Key strategic moves & developments
9.5 MANNKIND CORPORATION
9.5.1 Company overview
9.5.2 Operating Business Segment Overview
9.5.3 Business performance
9.5.4 Strategic moves and developments
9.5.5 Key strategic moves & developments
9.6.1 Company overview
9.6.2 Operating Business Segment Overview
9.6.3 Business performance
9.6.4 Strategic moves and developments
9.6.5 Key strategic moves & developments
9.7 MEDTRONIC, INC.
9.7.1 Company overview
9.7.2 Operating Business Segment Overview
9.7.3 Business Performance
9.7.4 Strategic moves and developments
9.7.5 Key strategic moves & developments
9.8 NOVO NORDISK
9.8.1 Company overview
9.8.2 Operating Business Segment Overview
9.8.3 Financial performance
9.8.4 Strategic moves and developments
9.8.5 Key strategic moves & developments
9.9.1 Company overview
9.9.2 Operating Business Segment Overview
9.9.3 Financial performance
9.9.4 Strategic moves and developments
9.9.5 Key strategic moves & developments
9.10 SENSEONICS HOLDING, INC.
9.10.1 Company overview
9.10.2 Operating Business Segment Overview
9.10.3 Financial performance
9.10.4 Strategic moves and developments
9.10.5 Key strategic moves & developments
Next generation diabetes therapy and drug delivery devices are used to check the blood glucose levels and deliver insulin into the body. Next generation diabetes drug delivery systems, such as oral and inhalable insulin, help introduce insulin into the patients body without causing pain and reduce the risk of skin irritation, owing to frequent use of needles. Advancements in diabetes therapy systems, such as insulin patch, continuous glucose monitoring (CGM) system, and artificial pancreas, are frequently used to detect the glucose levels and adjust the insulin levels to manage the change in glucose levels.
Rise in the number of diabetics and the benefits of using advanced diabetic devices, such as artificial pancreas and insulin patches over conventional products, are expected to boost the growth of next generation diabetes therapy and drug delivery market. Furthermore, the increase in disposable income among the diabetic patients and technological advancement of next generation diabetic products areanticipated to fuel the market growth. The rise in healthcare expenditure in the developing countries, such as India and China, is expected to provide opportunities for market expansion. However, lack of awareness, less variability in products, and cost restrains in the developing regions are expected to hamper the market growth.
CGM system is a well-established product and dominates the market, attributed to the presence of a large patient base suffering from diabetes with highest share in 2015, and is anticipated to continue this trend in the future, in terms of revenue. Advantages of these systems as compared to conventional diabetic products are ease of usage and efficient & early detection of change in blood glucose levels, which are expected to boost the growth of this segment.
Diagnostics/clinics was the highest contributor and is anticipated to continue its dominance during the analysis period, and has accounted for about half of the share of the global market in 2015, due to the increase in procurement of the products from diagnostics and clinics by diabetic patients.
In 2015, North America displayed maximum contribution to the total revenue generated, while Asia-Pacific is expected to witness the highest CAGR of 50.2%, due to rise in disposable income, improvement in healthcare expenditure, and increase in adoption rate of advanced diabetic products.
Key Findings of Next Generation Diabetes Therapy and Drug Delivery Market
Artificial pancreas segment is projected to grow at the highest rate during the analysis period.
CGM system was the highest revenue-generating segment, and is expected to continue its dominance in future.
North America dominated global next generation diabetes therapy and drug delivery market, and is projected to grow at a CAGR of 40%.
India is expected to grow highest in the Asia-Pacific region, registering a CAGR of 51.1%.
Diagnostic/clinic segment was the highest end user contributor towards the market during the analysis period.
The key companies profiled in the report include Abbott Laboratories, Medtronic, Inc., Sanofi, Novo Nordisk, MannKind Corporation, Enteris BioPharma, Dexcom, Inc., Senseonics Holding, Inc., Medtech, and Johnson & Johnson.